Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,069 across all filing types
Latest filing 2019-09-18 Audit Report / Informat…
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Oasmia offentliggör rapport avseende särskild utredning av ansvarsfrågor genomförd av revisionsbyrån Deloitte
Audit Report / Information Classification · 95% confidence The document is a short announcement (under 5,000 characters) regarding the publication of a special audit report conducted by Deloitte for Oasmia Pharmaceutical. It explicitly states that the full report is available on the company's website and provides a link to the document as an attachment. According to the 'Menu vs Meal' rule, since this is an announcement of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA). FY 2019
2019-09-18 Swedish
Oasmia offentliggör rapport avseende särskild utredning av ansvarsfrågor genomförd av revisionsbyrån Deloitte
Audit Report / Information Classification · 95% confidence The document is a short announcement (under 5,000 characters) regarding the publication of a special audit report conducted by Deloitte for Oasmia Pharmaceutical. It explicitly states that the full report is available on the company's website and provides a link to the document as an attachment. According to the 'Menu vs Meal' rule, since this is an announcement of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA). FY 2019
2019-09-18 Swedish
Oasmia offentliggör rapport avseende särskild utredning av ansvarsfrågor genomförd av revisionsbyrån Deloitte
Audit Report / Information Classification · 95% confidence The document is a short announcement (under 5,000 characters) regarding the publication of a special audit report conducted by Deloitte for Oasmia Pharmaceutical. It explicitly states that the full report is available on the company's website and provides a link to the document as an attachment. According to the 'Menu vs Meal' rule, since this is an announcement of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA). FY 2019
2019-09-18 Swedish
Oasmia publishes report on special investigation of liability issues conducted by audit firm Deloitte
AGM Information Classification · 95% confidence The document is a short announcement (under 4,000 characters) regarding the publication of a special examiner's report by Deloitte. It explicitly states that the report is available on the company's website and provides a link to an attachment. According to the 'Menu vs Meal' rule, since this is an announcement of a report rather than the full report itself, it is classified as a Report Publication Announcement (RPA).
2019-09-18 English
Oasmia publishes report on special investigation of liability issues conducted by audit firm Deloitte
AGM Information Classification · 95% confidence The document is a short announcement (under 4,000 characters) regarding the publication of a special examiner's report by Deloitte. It explicitly states that the report is available on the company's website and provides a link to an attachment. According to the 'Menu vs Meal' rule, since this is an announcement of a report rather than the full report itself, it is classified as a Report Publication Announcement (RPA).
2019-09-18 English
Oasmia publishes report on special investigation of liability issues conducted by audit firm Deloitte
AGM Information Classification · 98% confidence The document discusses the findings of a special examiner (Deloitte) regarding the responsibilities of the former Board of Directors, specifically to assist the forthcoming Annual General Meeting (AGM) in deciding whether to grant discharge of liability for the fiscal year ended April 30, 2019. The text explicitly mentions the recommendation regarding denial of discharge of liability at the AGM. Although it references an 'Audit Report' (Deloitte's findings), the primary context is the preparation and subject matter for the AGM vote concerning discharge of liability. This strongly links the content to the AGM process. Since the document itself is an announcement/summary (short length, referencing the full report being available elsewhere, and containing EU Market Abuse Regulation disclosure), it is not the full AGM presentation (AGM-R) or the full Audit Report (AR). It is an announcement related to the AGM's agenda items, specifically the discharge vote, which is often covered in proxy materials (PSI) or related to the AGM itself. Given the focus on the recommendation concerning the discharge of liability vote at the AGM, AGM-R is the most relevant category, as it pertains directly to the meeting's core governance decisions, even if this specific text is an announcement leading up to it. However, since the core subject is the investigation report intended to inform the discharge decision at the AGM, and the document is a press release announcing this information, it fits best as a general regulatory announcement (RNS) or potentially related to the proxy materials (PSI). Given the strong link to the AGM decision process, I will lean towards AGM-R as the subject matter, but acknowledge the format is an announcement. Since the content is about the grounds for the AGM decision on discharge, and not the meeting materials themselves, RNS is a safer fit for the announcement format, but AGM-R captures the substance better. Let's re-evaluate based on definitions. It is not a DEF 14A (Remuneration), nor a full AR. It is information directly feeding into the AGM vote on discharge. I will classify it as AGM-R because the entire purpose described is tied to the AGM's decision-making process regarding director liability.
2019-09-18 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.